Regado raises $60 million in follow-on

Regado Biosciences Inc. (NASDAQ:RGDO) raised $60 million through the sale of 10 million shares at $6 in a follow-on underwritten by Jefferies; Deutsche Bank; and Cowen. Regado proposed to raise up to $60 million in the offering on April 3, when its share price was $12.75.

Regado's REG1 Anticoagulation System is in the Phase III REGULATE-PCI trial to treat acute coronary syndrome (ACS) in patients undergoing percutaneous coronary intervention (PCI). REG1 is composed of pegnivacogin ( RB006), a pegylated, single-stranded RNA aptamer that binds to Factor IXa, and anivamersen ( RB007), a complementary single-stranded RNA containing a 15-nucleotide sequence that binds to and neutralizes pegnivacogin. ...